Pharma Mar Subsidiary Starts Phase 3 Trial of Tivanisiran for Dry Eye Disease

(PLX AI) – Pharma Mar says Sylentis, a subsidiary of Pharma Mar, initiates a new Phase III trial in the United States to evaluate the safety of tivanisiran in patients with dry eye disease.This Phase III study, called FYDES, will involve 26 …